The global liquid handling technology market was valued at USD 2.88 billion in 2017 and is expected to reach USD 5.55 billion in 2025, growing at a CAGR of 8.5% over the forecast period. The ability of advanced liquid handling platforms to reduce the timelines of sample processing has led to the high adoption rate, amongst drug development entities.
The use of genetic tools such as microarrays and PCR has greatly influenced genotyping studies, macromolecule interactions, and gene expression. Less laboratory area required and growing concern for the economical use of consumables by such techniques has fueled the demand for advanced sample processing workstations.
Pharmaceutical companies are making enormous investments in global drug R&D, particularly in developing countries such as China and India. Furthermore, the number of clinical studies registered with ClinicalTrials.gov has increased substantially from 101,125 in 2010 to more than 255,240 studies in 2017. More than 50% of these studies are focused on the development of drugs and biologics. Such a constant increase in research studies and funding has accelerated the adoption of liquid handling solutions.
The development of advanced liquid handlers enhances clinical research by reducing the development cost and facilitating the rapid launch of drugs. As a result, pharmaceutical companies are geared towards the adoption of advanced liquid handling systems for quick drug approval.
Manufacturers are engaged in the development of products to support variable customer needs concerning sample volume and application. For example, the launch of 96 and 384 channel automated and semi-automated liquid dispensing systems coupled with a broad range of consumables and accessories.
Market players have designed and developed platforms based on different technologies to improve the efficiency of liquid handling in complicated and sensitive processes. For instance, an introduction of Echo Liquid Handler by Labcyte, Inc. for contactless sample transfer using acoustics is a remarkable advancement in the market. This product reduces the risk of contamination which usually occurs due to disposable tips in conventional systems.
Products offered by the companies include automated workstations, small devices, and consumables. Automated workstations are projected to grow at the fastest CAGR owing to the rapid trend of automation in the pharma-biotech industry.
The companies are developing novel automated workstations using innovative technologies such as acoustic energy and Digital Microfluidics (DMF) as a result of the growing demand for automated solutions amongst research communities. This, in turn, is anticipated to contribute to the lucrative growth of this segment.
Although workstations and small devices are expensive, they account for a one-time, long-term investment for the user. Small devices segment incorporates handheld manual & electronic pipettes, burettes, pipette controllers, and few semi-automated systems. Consumables accounted for the largest revenue share owing to the high volume requirement of sample input coupled with frequent usage of consumables resulting in the repetitive purchase of products. This frequent purchase increases the expense for the laboratory professionals, which in turn, boosts revenue generation through this segment.
Automated, semi-automated, and manual solutions are the various type of liquid handling solutions currently available in the market. The introduction of novel genetic tools such as CRISPR & NGS has spurred the demand for automated platforms, as these tools have resulted in a rapid rise in the number of ongoing genetic research activities.
Currently, a substantial number of automated and semi-automated workstations are available in the market for usage across small to large scale research laboratories for various sample handling requirements. These workstations can be used in various liquid handling steps for different workflows such as PCR reaction, serial dilution, plate replication, and plate reformatting.
Furthermore, the high cost of fully automated systems and the increasing necessity of liquid handling solutions to accelerate research workflow are the two factors that are expected to drive the adoption of semi-automated systems. The demand for automation in repetitive steps such as sampling and liquid dispensing is expected to positively influence the uptake of semi-automated systems.
Microvolume liquid handling technologies have been underdeveloped in the past years. However, with an increase in number as well as the complexity of molecular biology research activities, there are ongoing developments for manufacturing liquid handling technologies for sample handling. Rising trends of high-throughput technologies and laboratory automation have fueled demand for liquid dispensing in various clinical workflows such as DNA sequencing, drug screening, and protein crystallization processes.
Earlier, liquid handlers were not used in the quality control processes during drug discovery and development due to the absence of protocols that can validate their performance. The introduction of novel liquid handling solutions has effectively addressed this challenge as the novel solutions can be assessed rapidly for their accuracy & specificity in sample transfer.
Liquid Handling Quality Assurance (LHQA) programs are designed to enable the implementation of these systems in various processes of drug development from compound preparation to clinical trials. The LHQA ensures process quality and reduces the overall cost & time of drug discovery, thereby contributing to the largest revenue share of the drug discovery & ADME-Tox in 2017.
Implementation of automated solutions has improved the reproducibility & quality of research programs in the life science industry. Emerging economies, such as China and India, are reported to invest heavily in the establishment and development of academic institutes and research facilities for genetic and stem cell studies. Moreover, these economies are also receiving funds from the state and central government.
Large universities & research institutes are recognized as the key contributors for the growth of academic & research institutes segment owing to the substantial number of ongoing PCR and microarray-based research activities at universities and research institutes. In addition to this, many biotech and pharma companies are observed to adopt automation in various processes.
The contract research organizations are expected to witness the fastest growth as a consequence of the rise in penetration of outsourcing of drug manufacturing processes. Moreover, the CROs are witnessing pressure concerning productivity and timelines, which in turn, is expected to positively impact the adoption of liquid handling solutions by CROs shortly.
North America dominated the market with the largest revenue share in 2017 owing to the rapid adoption of automation instruments in the U.S.-based research facilities. The major companies in the region are observed collaborating with well-established universities and research centers in Europe. This collaboration is the result of the presence of a substantial number of academic and research institutes in Europe.
However, emerging countries are witnessing notable developments in the pharmaceutical, biotechnology, and academic sectors, which in turn, is expected to drive the growth of the Asia Pacific market. Furthermore, high investment in life science sectors including omics research, advanced healthcare, microbiology, drug development, and clinical diagnostics by countries such as Japan and China is anticipated to accelerate market demand in this region.
Some key companies operating globally as the manufacturers of liquid handling technology-based products include Tecan Trading AG, LABCYTE INC., Hamilton Company, Gilson, Inc, Eppendorf AG, Labnet International, Inc., Borosil Glass Works Ltd., BioTek Instruments, Inc., Analytik Jena AG, Beckman Coulter, Inc., Aurora Biomed Inc., and Agilent Technologies.
Market players are embracing the trend of engaging in strategic partnerships with major pharma & biotech players to develop novel products. For instance, in February 2018, Brooks Life Sciences developed FluidX AcoustiX Sample Tube in partnership with AstraZeneca & Labcyte, Inc.
Report Attribute |
Details |
The market size value in 2020 |
USD 3.7 billion |
The revenue forecast in 2025 |
USD 5.54 billion |
Growth Rate |
CAGR of 8.5% from 2018 to 2025 |
The base year for estimation |
2017 |
Historical data |
2014 - 2017 |
Forecast period |
2018 - 2025 |
Quantitative units |
Revenue in USD Million and CAGR from 2018 to 2025 |
Report coverage |
Revenue forecast; company share; competitive landscape; growth factors and trends |
Segments covered |
Product, type, application, end-user, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; Germany; UK; Japan; China; Brazil; South Africa |
Key companies profiled |
Tecan Trading AG; LABCYTE INC.; Hamilton Company; Gilson; Inc; Eppendorf AG; Labnet International; Inc.; Borosil Glass Works Ltd.; BioTek Instruments; Inc.; Analytik Jena AG; Beckman Coulter; Inc.; Aurora Biomed Inc.; and Agilent Technologies. |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country; regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional & country levels and provides an analysis of the industry trends in each of the sub-segments from 2014 to 2025. For this study, Grand View Research has segmented the global liquid handling technology market report based on the product, type, application, end-use, and region:
Product Outlook (Revenue, USD Million; 2014 - 2025)
Automated Workstations
Standalone Workstations
Integrated Workstations
Small Devices
Pipettes
Electronic Pipettes
Manual Pipettes
Pipette Controllers
Burettes
Dispensers
Others
Consumables
Regents
Disposable Tips
Tubes & Plates
Others
Type Outlook (Revenue, USD Million; 2014 - 2025)
Automated Liquid Handling
Manual Liquid Handling
Semi-Automated Liquid Handling
Application Outlook (Revenue, USD Million; 2014 - 2025)
Drug Discovery & ADME-Tox Research
Cancer & Genomic Research
Bioprocessing/Biotechnology
Others
End-User Outlook (Revenue, USD Million; 2014 - 2025)
Academic & Research Institutes
Pharmaceutical & Biotechnology Companies
Contract Research Organizations
Regional Outlook (Revenue, USD Million; 2014 - 2025)
North America
The U.S.
Canada
Europe
Germany
UK
Asia Pacific
Japan
China
Latin America
Brazil
The Middle East and Africa (MEA)
South Africa
b. The global liquid handling technology market size was estimated at USD 3.4 billion in 2019 and is expected to reach USD 3.7 billion in 2020.
b. The global liquid handling technology market is expected to grow at a compound annual growth rate of 8.5% from 2018 to 2025 to reach USD 5.5 billion by 2025.
b. North America dominated the liquid handling technology market with a share of 39.9% in 2019. This is attributable to the rapid adoption of automation instruments in the U.S.-based research facilities.
b. Some key players operating in the liquid handling technology market include Tecan Trading AG, LABCYTE INC., Hamilton Company, Gilson, Inc, Eppendorf AG, Labnet International, Inc., Borosil Glass Works Ltd., BioTek Instruments, Inc., Analytik Jena AG, Beckman Coulter, Inc., Aurora Biomed Inc., and Agilent Technologies.
b. Key factors that are driving the market growth include an increase in investment in drug development, clinical trials, and life sciences R & D, rapid adoption of automation, and demand for effective miniaturization.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.
We value your investment and offer free customization with every report to fulfil your exact research needs.